SI1185272T1 - Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania - Google Patents

Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania

Info

Publication number
SI1185272T1
SI1185272T1 SI200030423T SI200030423T SI1185272T1 SI 1185272 T1 SI1185272 T1 SI 1185272T1 SI 200030423 T SI200030423 T SI 200030423T SI 200030423 T SI200030423 T SI 200030423T SI 1185272 T1 SI1185272 T1 SI 1185272T1
Authority
SI
Slovenia
Prior art keywords
carbamoylbenzofuran
cyanoindol
mania
piperazine
butyl
Prior art date
Application number
SI200030423T
Other languages
English (en)
Slovenian (sl)
Inventor
Gerd Bartoszyk
Christoph Seyfried
Amsterdam Christoph Van
Henning B�Ttcher
Ewen Sedman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1185272(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SI1185272T1 publication Critical patent/SI1185272T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200030423T 1999-05-27 2000-05-16 Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania SI1185272T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99109295 1999-05-27
PCT/EP2000/004376 WO2000072832A2 (en) 1999-05-27 2000-05-16 Novel use of 1-[4-(cyanoindol-3yl)butyl]-4-(carbamoyl-benzofuran-5yl)-piperazine and its physiologically acceptable salts
EP00935031A EP1185272B1 (en) 1999-05-27 2000-05-16 Novel use of 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania

Publications (1)

Publication Number Publication Date
SI1185272T1 true SI1185272T1 (en) 2004-12-31

Family

ID=8238153

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200030902T SI1410800T1 (sl) 1999-05-27 2000-05-16 Uporaba 1-4-(5-cianoindol-3-il)butil-4-(2-karbamoil-benzofuran-5-il)pipearazina in njegovih fiziolosko sprejemljivih soli
SI200030423T SI1185272T1 (en) 1999-05-27 2000-05-16 Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200030902T SI1410800T1 (sl) 1999-05-27 2000-05-16 Uporaba 1-4-(5-cianoindol-3-il)butil-4-(2-karbamoil-benzofuran-5-il)pipearazina in njegovih fiziolosko sprejemljivih soli

Country Status (31)

Country Link
US (4) US6900212B1 (xx)
EP (3) EP1410800B1 (xx)
JP (2) JP4884588B2 (xx)
KR (1) KR100683367B1 (xx)
CN (3) CN101869565A (xx)
AR (1) AR024112A1 (xx)
AT (3) ATE438399T1 (xx)
AU (1) AU771778B2 (xx)
BR (1) BR0010948A (xx)
CA (3) CA2372668C (xx)
CY (2) CY1105750T1 (xx)
CZ (1) CZ295623B6 (xx)
DE (3) DE60042710D1 (xx)
DK (3) DK1736158T3 (xx)
ES (3) ES2330774T3 (xx)
HK (1) HK1048444B (xx)
HU (1) HU229059B1 (xx)
IL (2) IL146707A0 (xx)
MX (1) MXPA01012172A (xx)
MY (1) MY135627A (xx)
NO (2) NO322120B1 (xx)
PL (3) PL199516B1 (xx)
PT (3) PT1736158E (xx)
RU (1) RU2237477C2 (xx)
SI (2) SI1410800T1 (xx)
SK (1) SK287851B6 (xx)
TR (1) TR200103361T2 (xx)
TW (1) TW518218B (xx)
UA (1) UA74337C2 (xx)
WO (1) WO2000072832A2 (xx)
ZA (1) ZA200110485B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10305739A1 (de) * 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
US20040192730A1 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction
WO2005094896A2 (en) * 2004-03-26 2005-10-13 Baylor University Targeted serotonin reuptake inhibitors
AU2007266890B2 (en) 2006-05-30 2011-02-17 Astrazeneca Ab 1, 3, 4 -oxadiazole derivatives as DGAT1 inhibitors
BRPI0821274A2 (pt) 2007-12-20 2017-06-13 Astrazeneca Ab composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
RU2011152517A (ru) 2009-06-19 2013-07-27 Астразенека Аб Пиразинкарбоксамиды в качестве ингибиторов dgat1
CN102762201B (zh) 2009-11-06 2013-12-18 爱思开生物制药株式会社 注意力缺陷/多动症的治疗方法
MX350745B (es) * 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2012131706A1 (en) 2011-03-20 2012-10-04 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
WO2013185209A1 (en) 2012-06-13 2013-12-19 Apotex Technologies Inc. Forms of vilazodone and processes for the preparation thereof
CN102860993A (zh) * 2012-10-16 2013-01-09 北京诚创思达医药科技有限公司 一种盐酸维拉唑酮快速释放片剂及其制备方法
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
WO2014116739A1 (en) 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses l-4-chlorokynurenine
EP2824104A1 (en) 2013-07-12 2015-01-14 Sandoz AG Process for the preparation of form III of Vilazodone hydrochloride
CA3024783A1 (en) * 2015-05-22 2016-12-01 Vistagen Therapeutics, Inc. Therapeutic uses of l-4-chlorokynurenine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
DE19514567A1 (de) 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) * 1998-03-09 2002-10-29 Pirelli Pneumatici S.P.A. Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1612813A3 (en) * 2001-09-11 2009-12-09 JTEKT Corporation Magnetizing device with pole array, and magnetizing method
FR2844591B1 (fr) * 2002-09-13 2005-04-15 Arvinmeritor Light Vehicle Sys Dispositif de determination du deplacement d'un arbre

Also Published As

Publication number Publication date
ATE438399T1 (de) 2009-08-15
HUP0201275A2 (en) 2002-08-28
JP4884588B2 (ja) 2012-02-29
DE60030338T2 (de) 2007-08-16
ATE337008T1 (de) 2006-09-15
DE60009697T2 (de) 2005-04-14
DK1736158T3 (da) 2009-11-02
US7371756B2 (en) 2008-05-13
CY1109472T1 (el) 2012-05-23
HU229059B1 (en) 2013-07-29
EP1736158B1 (en) 2009-08-05
US20050113386A1 (en) 2005-05-26
US6900212B1 (en) 2005-05-31
WO2000072832A2 (en) 2000-12-07
WO2000072832A3 (en) 2001-12-20
CN1679577A (zh) 2005-10-12
HK1048444B (zh) 2005-12-09
KR100683367B1 (ko) 2007-02-15
TR200103361T2 (tr) 2002-05-21
PL200490B1 (pl) 2009-01-30
DE60030338D1 (de) 2006-10-05
PL199516B1 (pl) 2008-09-30
CA2615271A1 (en) 2000-12-07
EP1185272B1 (en) 2004-04-07
PL199650B1 (pl) 2008-10-31
DE60009697D1 (de) 2004-05-13
CA2372668C (en) 2009-11-03
SK287851B6 (sk) 2012-01-04
IL146707A0 (en) 2002-07-25
EP1410800B1 (en) 2006-08-23
ATE263564T1 (de) 2004-04-15
BR0010948A (pt) 2002-04-23
CA2372668A1 (en) 2000-12-07
SI1410800T1 (sl) 2007-02-28
TW518218B (en) 2003-01-21
NO20015746L (no) 2001-11-26
DK1185272T3 (da) 2004-08-09
PL352373A1 (en) 2003-08-25
AU5066300A (en) 2000-12-18
EP1736158A3 (en) 2007-01-03
RU2237477C2 (ru) 2004-10-10
HK1048444A1 (en) 2003-04-04
NO322120B1 (no) 2006-08-14
DK1410800T3 (da) 2006-12-27
US20100063062A1 (en) 2010-03-11
EP1185272A2 (en) 2002-03-13
ES2219342T3 (es) 2004-12-01
KR20020008847A (ko) 2002-01-31
CN1198618C (zh) 2005-04-27
ES2271707T3 (es) 2007-04-16
CA2694866A1 (en) 2000-12-07
NO20061562L (no) 2001-11-26
CZ295623B6 (cs) 2005-09-14
CN1361692A (zh) 2002-07-31
EP1736158A2 (en) 2006-12-27
AU771778B2 (en) 2004-04-01
MXPA01012172A (es) 2002-07-22
CN101869565A (zh) 2010-10-27
US7642261B2 (en) 2010-01-05
NO324230B1 (no) 2007-09-10
NO20015746D0 (no) 2001-11-26
MY135627A (en) 2008-05-30
SK16462001A3 (sk) 2002-02-05
US20080119484A1 (en) 2008-05-22
CZ20014226A3 (cs) 2002-03-13
PT1736158E (pt) 2009-11-11
JP2003500441A (ja) 2003-01-07
IL146707A (en) 2007-06-03
CA2615271C (en) 2011-02-15
AR024112A1 (es) 2002-09-04
UA74337C2 (uk) 2005-12-15
CY1105750T1 (el) 2010-12-22
PT1185272E (pt) 2004-08-31
DE60042710D1 (de) 2009-09-17
ES2330774T3 (es) 2009-12-15
JP2011148799A (ja) 2011-08-04
ZA200110485B (en) 2003-06-30
PT1410800E (pt) 2007-01-31
HUP0201275A3 (en) 2004-04-28
EP1410800A1 (en) 2004-04-21

Similar Documents

Publication Publication Date Title
SI1185272T1 (en) Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania
IL158631A0 (en) 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1051504A1 (en) Use of compounds with 5-ht1a activity useful for treating disorders of the outer retina
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
ZA200402514B (en) 4[Piperidin-4-yliden-(3-carbamoylphenyl)methyl]benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders.
IL158704A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1047548A1 (zh) 包含有米氮平和哲比隆的治療抑鬱症及其它機能紊亂症的合成藥物
IL158703A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
EP0410114A3 (en) Use of 4-(4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl)-1-(4-fluorophenyl)-butanol in pharmaceutical compositions for the treatment of ischemia in brain
IL158632A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
IL150290A0 (en) The use of mirtazapine for the treatment of sleep disorders
IL158695A0 (en) 4-(phenyl-piperidin-4-yldine-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158630A0 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
PL347976A1 (en) Isonipecotamides for the treatment of integrin−mediated disorders
IL158628A0 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
AU2002354850A1 (en) 4-(benzylidene-amino)-3-(methylsulfanyl)-4H-(1, 2, 4) triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies
PL366390A1 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
PL376713A1 (pl) Zastosowanie pochodnych kwasu piperazynosulfonowego jako antagonistów CCR1 do leczenia zwłóknienia, choroby Alzheimera i innych zaburzeń
IL158700A0 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HUP0202145A3 (en) The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
IL130994A0 (en) Use of 1-[4-(3- trifluoromethylphenyl)- 1,2,3,6-tetrahydropyrid- 1-yl]-2- (6,7-dimethoxynapth-2- yl) ethane for preparing medicines for the treatment of cerebral and neuronal disorders
SI1539160T1 (sl) Piperidin-2,6-dion pamoatne soli in njihova uporaba za zdravljenje s stresom povezanih afektivnih motenj